Enpatoran not checked
EMD Serono Research & Development Institute, Inc. · M5049
FollowEvery change as it happens, and a Monday email
Trials
4 active
12 in total · 7 in the EU
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “Participants will receive a dose of Enpatoran orally twice daily from Day 1 to Day 168.”In the company’s words, NCT07332481 on ClinicalTrials.gov
- Tested for
- Systemic Lupus Erythematosus (SLE) (2 trials), Cutaneous Lupus Erythematosus (CLE) (2 trials), Systematic Lupus Erythematosus, Cutaneous Lupus Erythematosus, Systemic Lupus Erythematosus
- Main trialPhase 3
- “The purpose of this global, multicenter, Phase 3 study is to evaluate the efficacy and safety of enpatoran over 24 weeks in participants with active cutaneous manifestations of lupus erythematosus with or without systemic disease. Study details include: Study Duration: Up to 35 weeks. Treatment Duration: 24 weeks. Visit Frequency: every 4 weeks, with the exception of the Week 2 televisit. Study Intervention Name: Enpatoran, Placebo. Intervention Form: Film-coated tablet.”In the company’s words, NCT07332481 on ClinicalTrials.gov
- Other names
- M5049
Other drugs for Systemic Lupus Erythematosus (SLE)
- CenerimodViatris Innovation GmbH · Phase 3
- IanalumabNovartis · Phase 3
- UpadacitinibAbbVie · Phase 3
- QL1074Qilu Pharmaceutical · Phase 3
- Dapirolizumab pegolUCB Biopharma SRL · Phase 3
- Mycophenolate MofetilRoche · Phase 3
Coming up4
- 12 Aug 2028Phase 2 trial completes · ClinicalTrials.gov
- 24 May 2029Phase 3 trial completes · ClinicalTrials.gov
- 25 May 2029Phase 3 trial completes · ClinicalTrials.gov
- 1 Sep 2031Phase 3 trial completes · ClinicalTrials.gov
Changes1
Last 90 days- 10 NovStatus changed: Not yet recruiting to Recruiting · ClinicalTrials.gov NCT07840287
Trials12
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 3Recruiting | 24 May 2029 | A Study of Enpatoran in Participants With Cutaneous Manifestations of Lupus With or Without Systemic Disease | |
| Phase 3Recruiting | 25 May 2029 | A Study of Enpatoran in Participants With Cutaneous Manifestations of Lupus With or Without Systemic Disease (ELOWEN-2) | |
| Phase 3Recruiting | 1 Sep 2031 | A Long-Term Extension (LTE) Study Of Enpatoran In Cutaneous Manifestations Of Lupus With Or Without Systemic Disease [Elowen-LTE] | |
| Phase 2Active, not recruiting | 12 Aug 2028 | The Willow LTE Study With M5049 in Participants With SCLE, DLE and/or SLE (WILLOW LTE) | |
| Phase 2Completed | 16 Aug 2021 | Study of M5049 in Participants With COVID-19 Pneumonia (ANEMONE) | |
| Phase 2Completed | 20 Nov 2024 | The WILLOW Study With M5049 in SLE and CLE (SCLE and/or DLE) (WILLOW) | |
| Phase 2Terminated | 25 Jun 2025 | Study of M5049 in DM and PM Participants (NEPTUNIA) | |
| Phase 1Completed | 23 Nov 2021 | Study of M5049 in Healthy Japanese and Caucasian Participants | |
| Phase 1Completed | 24 Dec 2021 | Enpatoran Human Mass Balance and Absolute Bioavailability Study | |
| Phase 1Completed | 19 Dec 2023 | Study of M5049 in CLE and SLE Participants | |
| Phase 1Completed | 2 Dec 2024 | A TQT Study to Investigate the Effect of Enpatoran on Cardiac Repolarization in Healthy Participants | |
| Phase 1Completed | 13 Apr 2026 | Effect of Renal Impairment on Enpatoran Pharmacokinetics |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026